Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Cash Flow-to-Debt Ratio of -0.01x as of March 2026, meaning its operating cash flow of $-102.50K could theoretically repay 0% of its total liabilities ($18.17 Million) in one year. Check Drugs Made In America Acquisition II Cor earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Drugs Made In America Acquisition II Corp. Ordinary Shares across 2 annual periods. Also explore Drugs Made In America Acquisition II Cor assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
Year-by-year debt coverage analysis for Drugs Made In America Acquisition II Corp. Ordinary Shares. For market capitalisation and broader financial context, see market cap of Drugs Made In America Acquisition II Cor.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.06x | $-1.02 Million | $17.80 Million | ▲ +92.5% |
| 2024 | -0.76x | $-194.30K | $254.78K | — |